Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of MK-2060 in Older ESRD Participants
NCT03873038Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-2060 in thrombosis (6 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Any Adverse Event up to 164 days and Percentage of Participants With Any Serious Adverse Event up to 164 days. Started Apr 2019; status: completed.
02
Drugs
MK-2060
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03873038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873038.